Attomarker
Andrew Shaw has a diverse work experience in various fields. Andrew spent eight years as the Founder and Director of Research at EvanesCo Ltd, contributing to their research and development efforts. Andrew also served as the Founder and Director of Research at Attomarker Ltd, where they played a key role in developing a new multiplexed blood testing technology. As the CEO and Founder of Attomarker, they spearheaded the company's mission to revolutionize population health management through accurate blood testing in remote communities and homes. Additionally, Andrew held the position of Associate Professor of Physical Chemistry at the University of Exeter, where their research focused on accurate measurements and the development of techniques for profiling biological systems. Andrew also served as the Chairman of Arkiris, a joint initiative with QinetiQ and the University of Exeter, aimed at commercializing tailored electromagnetic materials inspired by the nanostructures found in butterfly wings.
Andrew Shaw has a Bachelor's degree in Natural Sciences from the University of Cambridge. Andrew then pursued a PhD in Gas Phase Physical Chemistry at the University of Southampton, which they completed between 1989 and 1992. It is not mentioned if they obtained any further degrees or conducted any specific studies at Stanford University.
This person is not in any teams
This person is not in any offices
Attomarker
Attomarker is a spin-out company from the University of Exeter, a member of the UK’s Russell Group of research-intensive universities. The company’s founder, Professor Andrew Shaw, leads a team of scientists and engineers across the UK & Germany. Backed by six patents and referenced in 17 academic journals, Attomarker works. Realising thevision that has inspired many, but has, until now, proved so hard to turn into reality. Patented Attomarker technology collects the blood on a disposable credit-card sized chip which slots into a mobile pocket-sized devise, docked to an iPhone. The camera visualises the blood tests which are then interpreted by the iPhone. Test results can be shared, linked to electronic patient record systems and an AI Symptom checker for diagnosis. A tele-consultation will be available via the phone. Planned launch tests include Food Allergy (covering the eight food allergens that account for 95% of all), Pregnancy (replacing unreliable and undignified urine tests) and C-reactive protein, the 21st C thermometer, (identifying infection faster than changes in temperature). Research projects that will follow include fifth generation HIV testing, infectious diseases such as Zika and Ebola, Alzheimer’s, immunotherapy cohort surveillance, sepsis and a vitamin panel test. Attomarker intends to develop three sales channels - private doctors, pharmacies and direct to consumer.